Hims & Hers Health Inc. Stock News

Hims & Hers Health shows strong growth in subscribers, revenue, and profitability, driven by expanding offerings and strategic partnerships, especially in weight loss and dermatology. HIMS posted stellar Q1 FY 2025: Revenue +110%, EBITDA +181%, EPS +300%. Growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Management's ambitious 2030 strategy leverages AI, new specialti...

This year has had its ups and downs on Wall Street, but some investments are rolling. There are 14 stocks with market caps north of $1 billion that have more than doubled so far in 2025 -- and some of the names will surprise you.

Our volatility scorecard has a pretty good feel for the market right now.

Hims & Hers Health continues to fire on all cylinders as a business, growing at extraordinary rates while also improving its margins. Today, I will offer a unique and simplified view of the business based on its recently announced, and very important, deal with Novo Nordisk. In short, based on Hims multi-product and multi-brand platform, which has generated sustained free cash flow for years no...

Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. “We are always looking for long-term, sustainable ways to increase access to care for our cus...

When investors choose to risk their capital in an individual company, they must be aware that the stock market isn't the one-sided machine it used to be a few decades ago. Thanks to the flow of information and availability in the digital space, today's market has become more interconnected than ever before.

Hims & Hers (HIMS -5.42%) has put investors on a roller coaster ride in 2025.